Researchers called the results of treatment using Venclexta (venetoclax) and Vidaza (azacitidine) “remarkably impressive.”

Imbruvica-based treatment may also work better than intensive chemotherapy for younger patients.

Customized cell therapy plus Imbruvica leads to high response rate.

Venclexta plus Gazyva reduces risk of disease progression or death.

Approval was based on improves progression-free survival in the MURANO trial.

Oncologists are excited about the increased options available to patients, and about the promise of even more new therapies to come.

Venclexta combination therapy clears leukemia in blood and bone marrow, recent studies show.

Revlimid improves outcomes for chronic lymphocytic leukemia patients, but better drugs are now available.